167 related articles for article (PubMed ID: 21562972)
61. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide.
Gadermaier E; Flicker S; Aberer W; Egger C; Reider N; Focke M; Vrtala S; Kundi M; Valenta R
Int Arch Allergy Immunol; 2010; 151(1):17-27. PubMed ID: 19672093
[TBL] [Abstract][Full Text] [Related]
62. Intranasal treatment with a recombinant hypoallergenic derivative of the major birch pollen allergen Bet v 1 prevents allergic sensitization and airway inflammation in mice.
Wiedermann U; Herz U; Baier K; Vrtala S; Neuhaus-Steinmetz U; Bohle B; Dekan G; Renz H; Ebner C; Valenta R; Kraft D
Int Arch Allergy Immunol; 2001 Sep; 126(1):68-77. PubMed ID: 11641608
[TBL] [Abstract][Full Text] [Related]
63. Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation.
Buczyłko K; van der Werf JF; Boot D; van Ree R
Int Arch Allergy Immunol; 2017; 172(3):183-186. PubMed ID: 28380494
[TBL] [Abstract][Full Text] [Related]
64. Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy.
Ferreira F; Hirtenlehner K; Jilek A; Godnik-Cvar J; Breiteneder H; Grimm R; Hoffmann-Sommergruber K; Scheiner O; Kraft D; Breitenbach M; Rheinberger HJ; Ebner C
J Exp Med; 1996 Feb; 183(2):599-609. PubMed ID: 8627171
[TBL] [Abstract][Full Text] [Related]
65. Recombinant allergens for pollen immunotherapy.
Wallner M; Pichler U; Ferreira F
Immunotherapy; 2013 Dec; 5(12):1323-38. PubMed ID: 24283843
[TBL] [Abstract][Full Text] [Related]
66. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study.
Pfaar O; Barth C; Jaschke C; Hörmann K; Klimek L
Int Arch Allergy Immunol; 2011; 154(4):336-44. PubMed ID: 20975285
[TBL] [Abstract][Full Text] [Related]
67. The Use of Biomarkers to Predict Aero-Allergen and Food Immunotherapy Responses.
Sindher SB; Long A; Acharya S; Sampath V; Nadeau KC
Clin Rev Allergy Immunol; 2018 Oct; 55(2):190-204. PubMed ID: 29455358
[TBL] [Abstract][Full Text] [Related]
68. Recombinant allergens for immunotherapy.
Valenta R; Niederberger V
J Allergy Clin Immunol; 2007 Apr; 119(4):826-30. PubMed ID: 17335886
[TBL] [Abstract][Full Text] [Related]
69. The clinical relevance of molecular diagnosis in children allergic to grass pollen and treated with allergen immunotherapy.
Barberi S; Traina G; Landi M; De Castro G; Peroni D; Licari A; Marseglia G; Ciprandi G
Allergol Immunopathol (Madr); 2019; 47(3):309-310. PubMed ID: 30738628
[No Abstract] [Full Text] [Related]
70. Immunotherapy with a recombinant hybrid molecule alleviates allergic responses more efficiently than an allergenic cocktail or pollen extract in a model of chenopodium album allergy.
Nouri HR; Sankian M; Afsharzadeh D; Varasteh A
Int Arch Allergy Immunol; 2013; 161(4):325-32. PubMed ID: 23689669
[TBL] [Abstract][Full Text] [Related]
71. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
[TBL] [Abstract][Full Text] [Related]
72. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy?
Witten M; Malling HJ; Blom L; Poulsen BC; Poulsen LK
J Allergy Clin Immunol; 2013 Nov; 132(5):1248-1252.e5. PubMed ID: 24035151
[No Abstract] [Full Text] [Related]
73. Clinical bystander effect exerted by allergen immunotherapy: a hypothesis.
Ciprandi G
Eur Ann Allergy Clin Immunol; 2015 Mar; 47(2):62-3. PubMed ID: 25781197
[TBL] [Abstract][Full Text] [Related]
74. Prevalence of IgE-binding to Art v 1, Art v 4 and Amb a 1 in mugwort-allergic patients.
Oberhuber C; Ma Y; Wopfner N; Gadermaier G; Dedic A; Niggemann B; Maderegger B; Gruber P; Ferreira F; Scheiner O; Hoffmann-Sommergruber K
Int Arch Allergy Immunol; 2008; 145(2):94-101. PubMed ID: 17823540
[TBL] [Abstract][Full Text] [Related]
75. Reduced anaphylactic potential of denatured pullulan-conjugated Cry j 1.
Utsumi D; Sugawara T; Hashida K; Yasuhara Y; Fujinami K; Lund K; Ohashi-Doi K
Int Immunopharmacol; 2021 Oct; 99():108026. PubMed ID: 34358858
[TBL] [Abstract][Full Text] [Related]
76. Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy.
Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
J Allergy Clin Immunol; 2014 Sep; 134(3):741-744.e5. PubMed ID: 24934275
[No Abstract] [Full Text] [Related]
77. Olive, grass or both? Molecular diagnosis for the allergen immunotherapy selection in polysensitized pollinic patients.
Moreno C; Justicia JL; Quiralte J; Moreno-Ancillo A; Iglesias-Cadarso A; Torrecillas M; Labarta N; García MA; Dávila I
Allergy; 2014 Oct; 69(10):1357-63. PubMed ID: 24988991
[TBL] [Abstract][Full Text] [Related]
78. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
Klimek L; Schendzielorz P; Pinol R; Pfaar O
Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
[TBL] [Abstract][Full Text] [Related]
79. Genetic engineering of recombinant hypoallergenic oligomers of the major birch pollen allergen, Bet v 1: candidates for specific immunotherapy.
Vrtala S; Hirtenlehner K; Susani M; Hufnagl P; Binder BR; Vangelista L; Pastore A; Sperr WR; Valent P; Ebner C; Kraft D; Valenta R
Int Arch Allergy Immunol; 1999; 118(2-4):218-9. PubMed ID: 10224386
[No Abstract] [Full Text] [Related]
80. Unique and cross-reactive T cell epitope peptides of the major Bahia grass pollen allergen, Pas n 1.
Etto T; de Boer C; Prickett S; Gardner LM; Voskamp A; Davies JM; O'Hehir RE; Rolland JM
Int Arch Allergy Immunol; 2012; 159(4):355-66. PubMed ID: 22832594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
